載入...
New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses
Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time of diagnosis and no pharmacological therapies yet approved by the U.S. Food and Drug Administration. To address the great unmet need for effective IPF therapy, a number of new drugs...
Na minha lista:
| 發表在: | Am J Respir Crit Care Med |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Thoracic Society
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4299574/ https://ncbi.nlm.nih.gov/pubmed/25090037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201403-0509PP |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|